Chinook Therapeutics Dirección

Dirección controles de criterios 3/4

El CEO de Chinook Therapeutics' es Eric Dobmeier , nombrado en Apr 2019, tiene una permanencia de 4.33 años. compensación anual total es $4.84M, compuesta por 12.4% salario y 87.6% primas, incluidas acciones y opciones de la empresa. posee directamente un 0.42% de las acciones de la empresa, por valor de $12.16M. La antigüedad media del equipo directivo y de la junta directiva es de 2.2 años y 3.5 años, respectivamente.

Información clave

Eric Dobmeier

Chief Executive Officer (CEO)

US$4.8m

Compensación total

Porcentaje del salario del CEO	12.4%
Permanencia del CEO	4.3yrs
Participación del CEO	0.4%
Permanencia media de la dirección	2.2yrs
Promedio de permanencia en la Junta Directiva	3.5yrs

Actualizaciones recientes de la dirección

Recent updates

Will Chinook Therapeutics (NASDAQ:KDNY) Spend Its Cash Wisely?

May 28

Companies Like Chinook Therapeutics (NASDAQ:KDNY) Are In A Position To Invest In Growth

Feb 14

Chinook Therapeutics: Multiple Shots On Goal For IgAN

Aug 31

Analysts Have Just Cut Their Chinook Therapeutics, Inc. (NASDAQ:KDNY) Revenue Estimates By 17%

Aug 12

Chinook Therapeutics GAAP EPS of -$0.61 in-line, revenue of $0.42M in-line

Aug 08

Chinook gets European orphan drug designation for BION-1301 for a type of kidney disease

Jul 05

Análisis de compensación del CEO

¿Cómo ha cambiado la remuneración de Eric Dobmeier en comparación con los beneficios de Chinook Therapeutics?
Fecha	Compensación total	Salario	Ingresos de la empresa
Jun 30 2023	n/a	n/a	-US$246m
Mar 31 2023	n/a	n/a	-US$216m
Dec 31 2022	US$5m	US$601k	-US$188m
Sep 30 2022	n/a	n/a	-US$118m
Jun 30 2022	n/a	n/a	-US$92m
Mar 31 2022	n/a	n/a	-US$97m
Dec 31 2021	US$4m	US$547k	-US$103m
Sep 30 2021	n/a	n/a	-US$160m
Jun 30 2021	n/a	n/a	-US$149m
Mar 31 2021	n/a	n/a	-US$114m
Dec 31 2020	US$6m	US$438k	-US$82m

Compensación vs. Mercado: La compensación total ($USD4.84M) de Eric está en línea con el promedio de empresas de tamaño similar en el mercado US ($USD6.66M).

Compensación vs. Ingresos: La compensación de Eric ha aumentado mientras la empresa no es rentable.

CEO

Eric Dobmeier (54 yo)

4.3yrs

Permanencia

US$4,841,699

Compensación

Mr. Eric L. Dobmeier, J.D., has been an Independent Director at Structure Therapeutics Inc. since December 2022. He is the President, Chief Executive Officer and Director of Chinook Therapeutics, Inc. sinc...

Equipo directivo

Nombre	Posición	Permanencia	Compensación	Propiedad
Eric Dobmeier	President	4.3yrs	US$4.84m	0.42% $ 12.2m
Tom Frohlich	Chief Operating Officer	2.2yrs	US$2.02m	0.21% $ 6.1m
Andrew King	Chief Scientific Officer	2.2yrs	US$2.23m	0.027% $ 773.8k
Eric Bjerkholt	Chief Financial Officer	2.8yrs	sin datos	0.054% $ 1.6m
Sukhi Thethy	Senior Vice President of Finance & Accounting	less than a year	sin datos	sin datos
Noopur Liffick	Senior Vice President of Investor Relations & Corporate Communications	no data	sin datos	sin datos
Kirk Schumacher	Senior VP & General Counsel	no data	sin datos	sin datos
Jodi Jamieson	Senior Vice President of Human Resources	no data	sin datos	sin datos
Alan Glicklich	Executive Officer	3.3yrs	US$2.41m	0.011% $ 318.7k
Delphine Imbert	Senior Vice President of CMC & Technical Operations	2.3yrs	sin datos	sin datos
Charlotte Jones-Burton	Senior Vice President of Product Development & Strategy	1.6yrs	sin datos	sin datos
Andrew Oxtoby	Chief Commercial Officer	less than a year	sin datos	sin datos

2.2yrs

Permanencia media

49yo

Promedio de edad

Equipo directivo experimentado: El equipo directivo de KDNY se considera experimentado (2.2 años antigüedad media).

Miembros de la Junta

Nombre	Posición	Permanencia	Compensación	Propiedad
Eric Dobmeier	President	4.3yrs	US$4.84m	0.42% $ 12.2m
Michelle Griffin	Independent Director	2.8yrs	US$233.60k	0.0046% $ 133.4k
Srinivas Akkaraju	Independent Director	4.1yrs	US$227.60k	0.0046% $ 133.4k
William Greenman	Independent Director	13.2yrs	US$233.10k	0.033% $ 955.0k
Mahesh Krishnan	Independent Director	1.4yrs	US$451.98k	0.0018% $ 51.6k
Jerel Davis	Independent Lead Director	4.7yrs	US$244.60k	0.62% $ 18.1m
Robert Azelby	Independent Director	less than a year	sin datos	0% $ 0
Dolca Thomas	Independent Director	2.8yrs	US$217.60k	0.019% $ 537.1k

3.5yrs

Permanencia media

54.5yo

Promedio de edad

Junta con experiencia: La junta directiva de KDNY se considera experimentada (3.5 años de antigüedad promedio).

Chinook Therapeutics Dirección

Dirección controles de criterios 3/4

Información clave

Actualizaciones recientes de la dirección

President notifies of intention to sell stock

Independent Lead Director recently sold US$6.1m worth of stock

Chief Scientific Officer exercised options and sold US$57k worth of stock

President exercised options and sold US$192k worth of stock

Chinook Therapeutics, Inc. Appoints Andrew Oxtoby as Chief Commercial Officer

President recently sold US$190k worth of stock

Recent updates

Novartis AG (SWX:NOVN) completed the acquisition of Chinook Therapeutics, Inc. (NasdaqGS:KDNY) from a group of shareholders.

Chinook Therapeutics, Inc.(NasdaqGS:KDNY) dropped from NASDAQ Biotechnology Index

Chinook Therapeutics, Inc.(NasdaqGS:KDNY) dropped from S&P TMI Index

Second quarter 2023 earnings released: US$0.94 loss per share (vs US$0.61 loss in 2Q 2022)

Chinook Therapeutics, Inc. Announces the First Patient Enrolled in its Phase 3 Second Study of Zigakibart (BION-1301) for Patients with IgA Nephropathy

Chinook Therapeutics, Inc. Presents Data from CHK-336 Phase 1 Trial in Healthy Volunteers and New Insights into the Role of Failure Repair in Chronic Kidney Disease at the 60th European Renal Association (ERA) Congress

Price target increased by 7.8% to US$39.45

Chinook Therapeutics to Present Updated Data from Zigakibart (BION-1301) Phase 1/2 Trial in Patients with IgA Nephropathy (IgAN) at the 60th European Renal Association (ERA) Congress

New major risk - Share price stability

Will Chinook Therapeutics (NASDAQ:KDNY) Spend Its Cash Wisely?

Consensus revenue estimates increase by 36%

Consensus revenue estimates increase by 273%

First quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

President notifies of intention to sell stock

Independent Lead Director recently sold US$6.1m worth of stock

Chief Scientific Officer exercised options and sold US$57k worth of stock

Consensus revenue estimates increase by 27%, EPS downgraded

Full year 2022 earnings: EPS and revenues exceed analyst expectations

President exercised options and sold US$192k worth of stock

Chinook Therapeutics, Inc. Appoints Andrew Oxtoby as Chief Commercial Officer

Companies Like Chinook Therapeutics (NASDAQ:KDNY) Are In A Position To Invest In Growth

President recently sold US$190k worth of stock

Chief Scientific Officer exercised options and sold US$191k worth of stock

Chief Operating Officer exercised options and sold US$246k worth of stock

President exercised options and sold US$657k worth of stock

Consensus forecasts updated

Chief Operating Officer notifies of intention to sell stock

Third quarter 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Chief Operating Officer exercised options and sold US$217k worth of stock

Chinook Therapeutics, Inc. Presents Updated Data from Atrasentan Phase 2 AFFINITY IgA Nephropathy (IgAN) Patient Cohort, Preclinical Atrasentan Research and Ongoing Clinical Trials at the American Society of Nephrology (ASN) Kidney Week 2022

Chief Operating Officer exercised options and sold US$145k worth of stock

Independent Director recently bought US$212k worth of stock

Chinook Therapeutics: Multiple Shots On Goal For IgAN

Consensus revenue estimates fall by 14%

Analysts Have Just Cut Their Chinook Therapeutics, Inc. (NASDAQ:KDNY) Revenue Estimates By 17%

Second quarter 2022 earnings: Revenues and EPS in line with analyst expectations

Chinook Therapeutics GAAP EPS of -$0.61 in-line, revenue of $0.42M in-line

Chief Scientific Officer exercised options and sold US$98k worth of stock

Chief Scientific Officer exercised options and sold US$89k worth of stock

Chinook gets European orphan drug designation for BION-1301 for a type of kidney disease

High number of new directors

President recently bought US$65k worth of stock

Consensus forecasts updated

Price target increased to US$34.86

Chinook Therapeutics, Inc. Presents Data from Atrasentan Phase 2 AFFINITY IgA Nephropathy (IgAN) Patient Cohort and Evotec Collaboration at 59th European Renal Association Congress 2022

Chinook Therapeutics Presents Updated Data from BION-1301 Phase 1/2 Trial in Patients with IgA Nephropathy (IgAN) and from Atrasentan Preclinical Mechanism of Action Studies at the 59th European Renal Association (ERA) Congress 2022

High number of new directors

Chinook Therapeutics, Inc., Annual General Meeting, May 26, 2022

Chief Scientific Officer exercised options and sold US$75k worth of stock

Chinook Therapeutics Announces Initiation of Phase 1 Healthy Volunteer Trial of CHK-336, a First-in-Class LDHA Inhibitor to Treat Hyperoxalurias

High number of new directors

Full year 2021 earnings: Revenues exceed analysts expectations while EPS lags behind

Chinook Therapeutics, Inc. Announces Resignation of Alan Glicklich as Chief Medical Officer, Effective February 11, 2022

High number of new directors

Análisis de compensación del CEO

CEO

Permanencia

Compensación

Equipo directivo

Permanencia media

Promedio de edad

Miembros de la Junta

Permanencia media

Promedio de edad